Table 7.
Risk of Brain Metastasis Associated with Each Marker in Breast Cancer with Regard to ErbB-2 Expression
| Brain metastasis marker⁎ | ErbB-2+ |
ErbB-2− |
||||
|---|---|---|---|---|---|---|
| Sensitivity† | Specificity† | P value‡ | Sensitivity† | Specificity† | P value‡ | |
| Novel markers | ||||||
| GRP94 | 8/8 (100) | 2/9 (22.2) | 0.47 | 4/5 (80) | 48/89 (53.9) | 0.19 |
| FN14 | 5/8 (62.5) | 6/9 (66.7) | 0.35 | 4/5 (80) | 68/88 (77.3) | 0.015 |
| TRAF2 | 6/7 (85.7) | 5/9 (55.6) | 0.15 | 3/4 (75) | 36/71 (50.7) | 0.62 |
| Traditional markers | ||||||
| ER | 3/7 (42.9) | 6/8 (75) | 0.61 | 2/4 (50) | 21/83 (25.3) | 0.28 |
| PR | 2/7 (28.6) | 6/7 (85.7) | 1.0 | 1/4 (25) | 29/81 (35.8) | 0.15 |
| Histologic grade III | 6/8 (75.0) | 3/9 (33.3) | 1.0 | 1/4 (25) | 42/45 (93.3) | 0.62 |
⁎
For novel markers, UniProtKB identifiers are as follows: GRP94, P14625; FN14, Q9NP84; TRAF2, Q12933. For traditional markers: estrogen receptor ER, P03372; progesterone receptor PR, P06401.
†
Variation in denominators derives from missing values in the IHC (eg, tissue lost, unviable staining, or background).
‡
Fisher's test.